News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
385,101 Results
Type
Article (18794)
Company Profile (289)
Press Release (366018)
Multimedia
Podcasts (51)
Webinars (8)
Section
Business (111698)
Career Advice (431)
Deals (21578)
Drug Delivery (54)
Drug Development (61866)
Employer Resources (52)
FDA (9350)
Job Trends (7643)
News (202559)
Policy (16959)
Tag
Academia (1262)
Accelerated approval (4)
Adcomms (15)
Allergies (67)
Alliances (28586)
ALS (82)
Alzheimer's disease (1107)
Antibody-drug conjugate (ADC) (109)
Approvals (9370)
Artificial intelligence (179)
Autoimmune disease (22)
Automation (8)
Bankruptcy (199)
Best Places to Work (6782)
BIOSECURE Act (7)
Biosimilars (52)
Biotechnology (238)
Bladder cancer (72)
Brain cancer (23)
Breast cancer (210)
Cancer (1843)
Cardiovascular disease (149)
Career advice (378)
Career pathing (5)
CAR-T (140)
Cell therapy (383)
Cervical cancer (15)
Clinical research (50808)
Collaboration (669)
Compensation (309)
Complete response letters (18)
COVID-19 (1415)
CRISPR (45)
C-suite (194)
Cystic fibrosis (92)
Data (1953)
Denatured (12)
Depression (40)
Diabetes (199)
Diagnostics (3092)
Digital health (7)
Diversity (2)
Diversity, equity & inclusion (18)
Drug discovery (98)
Drug pricing (61)
Drug shortages (17)
Duchenne muscular dystrophy (96)
Earnings (47957)
Editorial (29)
Employer branding (5)
Employer resources (46)
Events (62607)
Executive appointments (540)
FDA (10382)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (603)
Gene editing (106)
Generative AI (15)
Gene therapy (285)
GLP-1 (459)
Government (1958)
Grass and pollen (3)
Guidances (90)
Healthcare (9848)
Huntington's disease (25)
IgA nephropathy (26)
Immunology and inflammation (105)
Indications (24)
Infectious disease (1512)
Inflammatory bowel disease (129)
Inflation Reduction Act (10)
Influenza (32)
Intellectual property (83)
Interviews (61)
IPO (11499)
IRA (25)
Job creations (1238)
Job search strategy (335)
Kidney cancer (8)
Labor market (12)
Layoffs (238)
Leadership (7)
Legal (2942)
Liver cancer (52)
Lung cancer (246)
Lymphoma (120)
Machine learning (6)
Management (12)
Manufacturing (197)
MASH (60)
Medical device (6272)
Medtech (6274)
Mergers & acquisitions (10583)
Metabolic disorders (526)
Multiple sclerosis (70)
NASH (14)
Neurodegenerative disease (79)
Neuropsychiatric disorders (26)
Neuroscience (1585)
NextGen: Class of 2025 (2951)
Non-profit (1385)
Now hiring (22)
Obesity (270)
Opinion (147)
Ovarian cancer (72)
Pain (70)
Pancreatic cancer (73)
Parkinson's disease (130)
Partnered (10)
Patents (185)
Patient recruitment (100)
Peanut (40)
People (32114)
Pharmaceutical (50)
Pharmacy benefit managers (12)
Phase I (16981)
Phase II (23083)
Phase III (15892)
Pipeline (1110)
Policy (76)
Postmarket research (1272)
Preclinical (6978)
Press Release (36)
Prostate cancer (86)
Psychedelics (35)
Radiopharmaceuticals (230)
Rare diseases (345)
Real estate (2121)
Recruiting (19)
Regulatory (13563)
Reports (19)
Research institute (1213)
Resumes & cover letters (56)
Rett syndrome (5)
RNA editing (5)
RSV (24)
Schizophrenia (65)
Series A (115)
Series B (75)
Service/supplier (2)
Sickle cell disease (49)
Special edition (11)
Spinal muscular atrophy (132)
Sponsored (23)
Startups (2250)
State (1)
Stomach cancer (8)
Supply chain (40)
Tariffs (14)
The Weekly (38)
Vaccines (325)
Venture capitalists (35)
Weight loss (157)
Women's health (17)
Worklife (5)
Date
Today (243)
Last 7 days (661)
Last 30 days (2169)
Last 365 days (25316)
2025 (8642)
2024 (27066)
2023 (29975)
2022 (36152)
2021 (38045)
2020 (34015)
2019 (23991)
2018 (17744)
2017 (19641)
2016 (17036)
2015 (20753)
2014 (15137)
2013 (11197)
2012 (11471)
2011 (12022)
2010 (11392)
Location
Africa (286)
Alabama (45)
Alaska (3)
Arizona (99)
Arkansas (8)
Asia (26530)
Australia (5686)
California (4894)
Canada (1664)
China (437)
Colorado (191)
Connecticut (220)
Delaware (124)
Europe (51586)
Florida (678)
Georgia (156)
Idaho (21)
Illinois (312)
India (20)
Indiana (166)
Iowa (2)
Japan (130)
Kansas (68)
Kentucky (9)
Louisiana (8)
Maine (45)
Maryland (622)
Massachusetts (3840)
Michigan (96)
Minnesota (216)
Mississippi (1)
Missouri (48)
Montana (18)
Nebraska (9)
Nevada (48)
New Hampshire (49)
New Jersey (1423)
New Mexico (14)
New York (1342)
North Carolina (754)
North Dakota (6)
Northern California (2160)
Ohio (134)
Oklahoma (9)
Oregon (23)
Pennsylvania (1024)
Puerto Rico (8)
Rhode Island (20)
South America (449)
South Carolina (16)
Southern California (1869)
Tennessee (58)
Texas (669)
United States (17687)
Utah (103)
Virginia (111)
Washington D.C. (40)
Washington State (472)
West Virginia (2)
Wisconsin (24)
385,101 Results for "antisense therapeutics limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Quiver Bioscience Announces Collaboration with the Dup15q Alliance to Advance Antisense Oligonucleotide Therapeutic Program
March 20, 2025
·
3 min read
Press Releases
Alloy Therapeutics Announces a Target Specific Collaboration and License Agreement for use of AntiClastic™ Antisense Platform with Sanofi
January 8, 2025
·
4 min read
Business
Secarna Pharmaceuticals and Orbit Discovery Enter Collaboration to Discover and Develop Peptide-conjugated Targeted Antisense Oligonucleotide Therapeutics
Secarna Pharmaceuticals GmbH & Co. KG and Orbit Discovery Ltd. today announced that they have entered into a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics.
May 28, 2024
·
2 min read
Press Releases
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
March 13, 2025
·
3 min read
Business
Celanese and Secarna Pharmaceuticals Enter into RNA Research Collaboration for Long-Acting Antisense Therapies
Celanese Corporation (NYSE: CE), a global specialty materials and chemical company, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European antisense drug discovery and development company, today announced a research collaboration for the development of long-acting implants that deliver antisense oligonucleotides (ASOs).
March 20, 2024
·
4 min read
Press Releases
TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
May 2, 2025
·
6 min read
ALS
Lilly Deepens ALS Pipeline With $415M Alchemab Licensing Deal
The Alchemab deal will further strengthen Lilly’s early-stage pipeline for amyotrophic lateral sclerosis, coming less than a year after the pharma licensed QurAlis’ antisense oligonucleotide to correct a specific protein alteration in ALS.
May 6, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Health Canada approves IMFINZI® (durvalumab) as the first and only immunotherapy regimen for adult patients with limited-stage small cell lung cancer (LS-SCLC)
April 10, 2025
·
6 min read
Press Releases
Antisense and RNAi Therapeutics Market Size to Surge USD 30.03 Bn by 2033: 19.12% CAGR Growth Outlook
August 7, 2024
·
14 min read
Press Releases
Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera
December 23, 2024
·
6 min read
1 of 38,511
Next
